Cardiac Remodeling

Dapagliflozin and Cardiac Remodeling in Chronic Kidney Disease: New Evidence for Cardioprotection

By MedXY 10/30/2025

Dapagliflozin reduces left ventricular mass index in chronic kidney disease patients, revealing a key mechanism for cardioprotective effects of SGLT2 inhibitors and highlighting early treatment benefits.

Cardiology Diabetes & Endocrinology Specialties

Untangling Adiposity and Insulin Resistance in HFpEF: Clarifying Their Distinct Impact on Cardiac Function

By MedXY 08/22/2025

This study reveals that excess adiposity, rather than insulin resistance or diabetes, predominantly drives left heart abnormalities and elevated pulmonary pressures in HFpEF, highlighting the need for targeted cardiometabolic therapies beyond glucose control.

Cardiology news Specialties

Aficamten in Obstructive Hypertrophic Cardiomyopathy: Durable 48-Week Benefits and Insights on Combination Therapy

By MedXY 08/17/2025

Aficamten shows sustained obstruction relief, symptom improvement, and favorable cardiac remodeling over 48 weeks in obstructive hypertrophic cardiomyopathy, with safe discontinuation of disopyramide possible.